Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Cybin Inc N.CYBN

Alternate Symbol(s):  CYBN

Healthcare Drug Manufacturers - Specialty & Generic
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NEO:CYBN)

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Business Wire 4 days ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Business Wire 8 days ago

Cybin launches new program phase to treat Major Depressive Disorder

Jonathon Brown 9 days ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Business Wire 9 days ago

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Business Wire October 31, 2024

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program

Business Wire October 24, 2024

Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024

Business Wire October 3, 2024

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

Business Wire October 1, 2024

Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Business Wire September 24, 2024
View More News ››

Opinion & Analysis (NEO:CYBN)

A Company on a Mission to Revolutionize Mental Healthcare. Here’s How.

Dave Jackson February 1, 2022

The Psychedelic Opportunity You Need to Know About

Dave Jackson October 20, 2021

Revolutionizing Mental Health Treatment

Featured Submission August 16, 2021

A New Frontier in Psychedelic Therapeutics

Featured Submission January 12, 2021

A Psychedelic & Nutraceutical Opportunity: A Boost for the Brain and Your Portfolio

Dave Jackson September 22, 2020
View More Opinion ››

Bullboard Posts (NEO:CYBN)

Vote for holders.

We will be making changes soon once the votes are completed.Hold or not?Good Future.
Tulsa123 - August 21, 2024

InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (Cboe

JUST IN: $CYBN InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Sees "Swell" of Insider Investments...
whytestocks - July 8, 2024

RE:Today’s news

What do you think?
Tulsa123 - June 12, 2024

Today’s news

Mushrooms used soon for suicidal migraines causes.interesting 
Tulsa123 - June 12, 2024

Globe says MindMed, Cybin get nod from U.S. FDA

2024-04-08 07:12 ET - In the News See In the News (C-MMED) Mind Medicine (MindMed) Inc (2) The Globe and Mail reports in its...
Tardis - April 8, 2024

Very Smart Money Bought In

Buy on any weakness IMO. This sector is and will continue to recieve serious attention. Cybin will be the belle of the ball IMHO...
Tardis - March 19, 2024
View more Bullboard ››

Nurcapital Corp Ltd

Nurcapital Corp Ltd

Nurcapital Corporation Ltd. is a Canada-based capital pool company. The Company is engaged in identifying and evaluating ...
View More »